Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study

被引:15
作者
Hawley, Samuel [1 ]
Javaid, M. Kassim [1 ,2 ]
Rubin, Katrine H. [3 ]
Judge, Andrew [1 ,2 ]
Arden, Nigel K. [1 ,2 ]
Vestergaard, Peter [4 ,5 ]
Eastell, Richard [6 ]
Diez-Perez, Adolfo [7 ,8 ]
Cooper, Cyrus [1 ,2 ]
Abrahamsen, Bo [3 ,9 ]
Prieto-Alhambra, Daniel [1 ,2 ,7 ,8 ,10 ]
机构
[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Musculoskeletal Biomed Res Unit, Oxford Natl Inst Hlth Res NIHR, Oxford, England
[2] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England
[3] Univ Southern Denmark, Inst Clin Res, Odense Patient Data Explorat Network OPEN, Odense, Denmark
[4] Aalborg Univ Hosp, Dept Clin Med, Aalborg, Denmark
[5] Aalborg Univ Hosp, Dept Endocrinol, Aalborg, Denmark
[6] Univ Sheffield, Dept Human Metab, Sheffield, S Yorkshire, England
[7] Univ Autonoma Barcelona, Hosp del Mar Med Res Inst IMIM, E-08193 Barcelona, Spain
[8] Inst Salud Carlos III, Red Temat Invest Cooperat Envejecimiento & Fragil, Barcelona, Spain
[9] Glostrup Cty Hosp, Res Ctr Ageing & Osteoporosis, Glostrup, Denmark
[10] Univ Autonoma Barcelona, Jordi Gol Primary Care Res Inst, Inst Invest Atencio Primaria IDIAP, Grp Recerca Malalties Prevalents Aparell Locomoto, E-08193 Barcelona, Spain
基金
英国医学研究理事会;
关键词
OSTEOPOROSIS; BISPHOSPHONATES; TREATMENT FAILURE; EPIDEMIOLOGY; FRACTURES; POSTMENOPAUSAL WOMEN; TREATMENT FAILURE; OSTEOPOROSIS TREATMENT; ZOLEDRONIC ACID; RISK-FACTORS; HEALTH-CARE; ALENDRONATE; PERSISTENCE; THERAPY; MEDICATION;
D O I
10.1002/jbmr.2595
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oral bisphosphonates (BPs) are highly effective in preventing fractures and are recommended first-line therapies for patients with osteoporosis. We identified the incidence and predictors of oral BP treatment failure, defined as the incidence of two or more fractures while on treatment (>= 2 FWOT) among users with high adherence. Fractures were considered from 6 months after treatment initiation and up to 6 months after discontinuation. Data from computerized records and pharmacy invoices were obtained from Sistema d`Informacio per al Desenvolupament de l`Investigacio en Atencio Primaria (SIDIAP; Catalonia, Spain) and Danish Health Registries (Denmark) for all incident users of oral BPs in 2006-2007 and 2000-2001, respectively. Fine and Gray survival models using backwardstepwise selection (p-entry 0.049; p- exit 0.10) and accounting for the competing risk of therapy cessation were used to identify predictors of >= 2 FWOT among patients having persisted with treatment >= 6 months with overall medication possession ratio (MPR) >= 80%. Incidence of >= 2 FWOT was 2.4 (95% confidence interval [CI], 1.8 to 3.2) and 1.7 (95% CI, 1.2 to 2.2) per 1000 patient-years (PYs) within Catalonia and Denmark, respectively. Older age was predictive of >= 2 FWOT in both Catalonian and Danish cohorts: subhazard ratio (SHR) = 2.28 (95% CI, 1.11 to 4.68) and SHR = 2.61 (95% CI, 0.98 to 6.95), respectively, for 65 to < 80 years; and SHR = 3.19 (95% CI, 1.33 to 7.69) and SHR = 4.88 (95% CI, 1.74 to 13.7), respectively, for >= 80 years. Further significant predictors of >= 2 FWOT identified within only one cohort were dementia, SHR = 4.46 (95% CI, 1.02 to 19.4) (SIDIAP); and history of recent or older fracture, SHR = 3.40 (95% CI, 1.50 to 7.68) and SHR = 2.08 (95% CI: 1.04-4.15), respectively (Denmark). Even among highly adherent users of oral BP therapy, a minority sustain multiple fractures while on treatment. Older age was predictive of increased risk within both study populations, as was history of recent/old fracture and dementia within one but not both populations. Additional and/or alternative strategies should be investigated for these patients. (c) 2015 American Society for Bone and Mineral Research.
引用
收藏
页码:234 / 244
页数:11
相关论文
共 36 条
[1]   Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study [J].
Abrahamsen, B. ;
Rubin, K. H. ;
Eiken, P. A. ;
Eastell, R. .
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) :321-328
[2]   Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate [J].
Abrahamsen, Bo ;
Eiken, Pia ;
Eastell, Richard .
ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (11) :998-1004
[3]   Osteoporosis treatment and fracture incidence: the ICARO longitudinal study [J].
Adami, S. ;
Isaia, G. ;
Luisetto, G. ;
Minisola, S. ;
Sinigaglia, L. ;
Silvestri, S. ;
Agnusdei, D. ;
Gentilella, R. ;
Nuti, R. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (08) :1219-1223
[4]   Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study [J].
Adami, Silvano ;
Isaia, Giancarlo ;
Luisetto, Giovanni ;
Minisola, Salvatore ;
Sinigaglia, Luigi ;
Gentilella, Raffaella ;
Agnusdei, Donato ;
Iori, Nicoletta ;
Nuti, Ranuccio .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (10) :1565-1570
[5]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[6]   Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].
Black, DM ;
Thompson, DE ;
Bauer, DC ;
Ensrud, K ;
Musliner, T ;
Hochberg, MC ;
Nevitt, MC ;
Suryawanshi, S ;
Cummings, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124
[7]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[8]   Spectroscopic markers of bone quality in alendronate-treated postmenopausal women [J].
Boskey, A. L. ;
Spevak, L. ;
Weinstein, R. S. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (05) :793-800
[9]   Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis [J].
Cairoli, E. ;
Eller-Vainicher, C. ;
Ulivieri, F. M. ;
Zhukouskaya, V. V. ;
Palmieri, S. ;
Morelli, V. ;
Beck-Peccoz, P. ;
Chiodini, I. .
OSTEOPOROSIS INTERNATIONAL, 2014, 25 (04) :1401-1410
[10]   The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008